Piper Sandler Taps Aamer Naseer to Lead Booming Life Sciences Division

MINNEAPOLIS, MN – February 25, 2026 – Piper Sandler Companies (NYSE: PIPR) has announced a significant leadership appointment, naming 25-year industry veteran Aamer Naseer as the global head of life sciences outsourcing and B2B med tech. The strategic move signals the investment bank's intent to deepen its foothold in two of the most dynamic and rapidly consolidating sectors in global healthcare.

The appointment comes as both life sciences outsourcing and medical technology are experiencing unprecedented growth and a resurgence in deal-making. J.P. Peltier, global co-head of investment banking and capital markets at Piper Sandler, underscored the strategic value of the appointment. “Aamer has built deep relationships across the life sciences ecosystem and has a strong track record of advising private equity firms, public companies and founders/entrepreneurs,” Peltier stated. “His leadership, sector expertise and commitment to our clients position us exceptionally well to continue expanding our capabilities in this important and evolving space.”

Naseer, who has been a Managing Director with the firm since 2006, steps into the role at a critical juncture for the industry. The complex landscape requires seasoned guidance, a point Naseer himself addressed. “This sector continues to evolve and consolidate rapidly and our clients are navigating increasingly dynamic strategic decisions,” Naseer said. “I’m looking forward to supporting our clients and driving meaningful outcomes across the life sciences outsourcing and the B2B med tech landscape.”

A Strategic Move in a High-Growth Arena

Piper Sandler’s decision to create this global leadership role is anchored in powerful market trends. The life sciences outsourcing market, encompassing Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs), is on a steep upward trajectory. Valued at over $233 billion in 2024, the sector is projected to more than double, reaching an estimated $459 billion by 2032, driven by a compound annual growth rate of nearly 9%. This expansion is fueled by rising pharmaceutical R&D investments, the complexity of developing biologics, and a relentless corporate push for cost-efficiency and operational focus.

Simultaneously, the B2B medical technology space is witnessing a significant rebound in M&A activity. After a slowdown in recent years, 2024 and 2025 saw a resurgence in deal-making that is expected to continue. The global MedTech industry, valued at over $668 billion in 2024, is benefiting from demographic shifts like aging populations and a wave of innovation in areas such as AI-driven diagnostics, surgical robotics, and remote patient monitoring. Large strategic acquirers are actively hunting for novel technologies to bolster their portfolios, while private equity firms remain drawn to the sector's robust returns and resilient customer base.

By placing a dedicated global head over these converging sectors, Piper Sandler is positioning itself to capitalize on the immense transaction potential and provide specialized advisory services to companies navigating this high-stakes environment.

The Architect of Deals: A Quarter-Century of Sector Mastery

Aamer Naseer brings a formidable resume to his new role. With over 25 years in the financial industry, his career includes formative years in the healthcare investment banking group at Lehman Brothers and an eight-year tenure at Bank of America. Since joining Piper Sandler in 2006, he has established himself as a leading advisor in the healthcare space.

His expertise is not merely financial but deeply rooted in the industry's operational fabric. Naseer has advised a diverse array of public and private companies, from medical manufacturing businesses and outsourcing service providers to the major MedTech OEMs. His experience spans a wide range of high-growth medical device sectors, including orthopedic, cardiology, dental, aesthetic, and ophthalmology. This granular understanding of different market niches, combined with an MBA from the prestigious Wharton School, provides him with a unique perspective on the strategic challenges and opportunities facing his clients.

This background makes him an ideal leader to guide founders, corporate boards, and private equity sponsors through the intricate process of mergers, acquisitions, and capital raises in a market defined by rapid technological change and regulatory hurdles.

Reinforcing a Market-Leading Position

While Naseer’s appointment marks a new chapter, it builds upon a long-established foundation of leadership for Piper Sandler in the healthcare sector. The firm is not entering the field but rather reinforcing its dominant position. According to industry data, Piper Sandler has ranked as the top Med-Tech M&A financial advisor by deal volume since 2012 and has successfully completed over 600 healthcare M&A transactions since 2010.

Its healthcare investment banking division is a powerhouse, with over 40 senior bankers dedicated to specialized verticals including Med-Tech, Healthcare Services, Biopharma, and Tools and Diagnostics. The firm's recent analyses indicate a strong outlook for 2026, with analysts anticipating a robust deal flow for both public and private assets. Key areas identified for potential M&A activity include mechanical thrombectomy, neuromodulation, minimally invasive glaucoma surgery (MIGS), cardiac monitoring, and soft tissue robotics—all sectors where deep expertise is paramount.

Naseer's new mandate is to harness this existing strength and drive further growth, ensuring the firm remains the go-to advisor for an industry in constant motion. His leadership is expected to sharpen the firm's focus and enhance its ability to execute complex cross-border transactions and strategic advisory assignments.

Navigating a Competitive and Consolidating Landscape

The investment banking world is fiercely competitive, particularly in lucrative, specialized sectors like healthcare. The so-called “talent war” for experienced bankers who bring deep client relationships and a proven deal sheet is intense. In this context, elevating a long-serving, high-performing internal leader like Naseer represents a significant strategic move, securing top-tier expertise to defend and expand market share against a host of global and boutique competitors.

Naseer’s own commentary on a rapidly consolidating sector highlights the central challenge for clients and the core value proposition of his team. As smaller innovators are acquired by larger strategic players and PE firms roll up assets to build platforms, companies face critical decisions about whether to sell, acquire, or raise capital to scale independently. Guiding clients through these pivotal moments requires not just financial acumen, but an intimate knowledge of the competitive landscape and technological frontiers. With Naseer at the helm of this crucial practice, Piper Sandler is poised to be a central player in shaping the future of the life sciences and MedTech industries.